Elon Musk is a known figure in the world of electric cars, space exploration, and most recently, social media. Now, the entrepreneur is pushing boundaries in a new way with brain-computer interfaces (BCI). His company, Neuralink, recently announced the completion of their first brain chip implant in a human patient. Questions of risks, opportunities, and ethics have grown around this newest endeavor.
Community Neuroscience Climate Science Alzheimer's
The effects of climate change continue to rise across the globe, with increased occurrences of extreme and intense weather. The consequences not only impact the environment, but the changes pose a significant threat to our health.
Community Neuroscience Rehabilitation
The widely watched U.S. Senate race between Pennsylvania Lieutenant Governor John Fetterman and Mehmet Oz, MD, has stoked conversation and questions about strokes.
In May, on the way to a campaign event, Fetterman had a stroke that his wife has said she recognized when he began slurring words and the left side of his face began drooping. During his Oct. 25 televised debate with Oz, Fetterman began by addressing “the elephant in the room.”
CPR
July 25, 2024
In Colorado and across the nation, emergency departments at pediatric hospitals are overflowing with kids who need intensive mental health treatment.
9News
July 23, 2024
A little more than a month after the Olympics wrap up, women triathletes will be heading to the south of France for another competition on the global stage.
Healthy Debate
July 18, 2024
In 1961, Yuri Gagarin became the first human in space. With every kilometre he ascended, he pushed the boundaries of human achievement and catalyzed a surge of interest in exploration, research, development – and medical innovation.
Medscape
July 18, 2024
Experts debating the pressing issue of how to prioritize patients in the increasingly common scenario of loss of access or insurance coverage for anti-obesity glucagon-like peptide 1 (GLP-1) receptor agonist drugs argued that comorbidities and obesity severity should strongly warrant continued coverage — while offering key strategies for getting and retaining approval from payers.
Mara Kalinoski
